INTRODUCTION
This national programme of obstructive sleep apnoea deals with the prevention and treatment of the disease. The term''sleep apnoea'' is used to refer to an illness that results in daytime symptoms because of abnormal cessations of respiration during sleep. There are other forms of sleep disorders but they are referred in this programme only in connection with di¡erential diagnosis.
According to Finnish population studies, the Health 2000 survey by the National Public Health Institute (Aromaa et al., 2002) and the register of hospital treatment periods (HILMO) of Finnish National Research and Development Centre for Welfare and Health (Stakes), approximately 150 000 Finnish patients su¡er from sleep apnoea. Up to 3% of middle-aged men and 2% of middleaged women have the illness in Finland. The number of patients with sleep apnoea and other sleep disorders is underestimated by diagnosis and is increasing. The studies on the prevalence of sleep apnoea in other countries have ¢gures from 0.8% (Gleadhill et al.,1991) to10% (Bearpark et al.,1995) .
Obesity is the most important risk factor for sleep apnoea. The main target of prevention and treatment is to achieve lower weight and weight control. Other treatment methods of sleep apnoea, particularly nasal continuous positive air pressure (n-CPAP) treatment, are individually initiated by specialist care. The main responsibility for helping patients in reducing weight and weight control will be in public health care.
The national programme has the following goals: (1) a decrease in the incidence of sleep apnoea; (2) full recovery of as many sleep apnoea patients as possible; (3) maintenance of good functional and working ability of sleep apnoea patients; (4) a decrease in the number of patients with severe sleep apnoea; (5) a decrease in the number of sleep apnoea patients requiring hospitalisation; and (6) an improvement in the cost^e¡ect ratio of sleep apnoea treatment. The most important measures towards achieving these goals include: (1) stepping up prevention of obesity and promoting weight reduction and weight control; (2) ensuring children's nasal breathing and intensifying the removal of obstructive adenoid tissue; (3) steeping up treatment of malocclusions and deviations in maxillomandibular growth in children; (4) increasing key group's knowledge of risk factors of sleep apnoea and the treatment of the disease; (5) stepping up early diagnostics and active treatment; (6) initiating early individual rehabilitation as part of the treatment; and (7) emphasising the importance of research.
The implementation of this national programme is vital. Regional direction and training will mainly be organized by hospital districts and/or provincial governments and local health-care centres. Special attention must be paid on the evaluation of the success of sleep apnoea prevention and treatment. Both special follow-up studies by Finnish Lung Health Association and population studies by the National Public Health Institute as well as HILMO by Stakes will be used in the evaluation of the programme.
FOREWORD
Sleep apnoea is a disease a¡ecting approximately150 000 Finns. Untreated sleep apnoea not only leads to an increase in mortality, the number of accidents, and the incidence of cardiovascular diseases, but also reduces working and functioning capacity, and undermines the quality of life. The signi¢cance of the problem in terms of national health and economy, the increasing patient numbers, the knowledge of improved possibilities for preventing and treating the disease, and the need for large-scale collaboration create the foundation for a national prevention programme.
After reaching an agreement with the Finnish Ministry of Social A¡airs and Health, the Finnish Lung Health Association appointed a working group to prepare a programme for the prevention and treatment of sleep apnoea for a10 The national programme is a recommendation to be applied to the prevention and treatment of sleep apnoea throughout the ¢eld of health care. The programme should be revised when necessary as medical knowledge increases and the equipment and medical treatments develop. The patient and the health-care professional and unit treating him are responsible for the actual treatment. The programme is based on numerous study results, reports and practical experience. Detailed references to published material are not given in the text, but examples of key literature have been gathered in an Appendix.
The Ministry of Social A¡airs and Health hopes that the programme will become a practical tool in the prevention of sleep apnoea.
Markku Lehto Permanent Secretary
SLEEP APNOEA AS AN ILLNESS De¢nitions
Occasional short-term interruptions in breathing occur during normal sleep. If the episodes are long-term or frequent and result in symptoms during waking hours, the condition can be de¢ned as sleep apnoea. In literature, the terms sleep apnoea syndrome or sleep apnoea illness are also used. In this programme, the term sleep apnoea is used to refer to an illness with abnormal respiratory interruptions during sleep.
Various forms of sleep apnoea and the associated terms are explained inTable 1. The events of obstructive apnoea are described in Appendix 1. This programme deals with the prophylaxis and treatment of obstructive sleep apnoea. Reference to other sleep disorders is only made in connection with di¡erential diagnosis.
The de¢nitions of sleep apnoea combine the symptoms of the patient and the ¢ndings from various test methods. Table 2 shows the diagnostic criteria of sleep apnoea in adults suitable for clinical work. Special 
Degrees of severity
The degree of severity is de¢ned on the basis of the number of respiratory disruptions [apnoea-hypopnoea index AHI] and the severity of daytime symptoms. The AHI shows how many episodes of apnoea and hypopnoea have been detected during 1h of sleep. In practice, the evaluation of the severity of sleep apnoea (Table 3) is complicated by the fact that the number of respiratory disruptions and the decrease in oxygen saturation measured by pulse oxymeter are not always directly proportional to the patient's symptoms.
Symptoms
The primary symptoms of sleep apnoea are respiratory interruptions. Primary symptoms also include abnormal daytime fatigue, which may be manifested as a tendency to doze o¡, a lack of concentration, or an impairment of memory function. Snoring may be the ¢rst sign of incipient obstruction of the airways. Snoring associated with sleep apnoea is generally habitual snoring, i.e. regular snoring occurring almost every night. The relationship of the symptoms to sleep apnoea is presented in Fig. 1 and the symptoms of sleep apnoea inTable 4.The evaluation of the severity of the symptoms is explained in Appendix 2. The special features of sleep apnoea in children are discussed in the chapter ''Special features of sleep apnoea in children''. 
Prevalence
Sleep apnoea is a common illness occurring in up to 3% of middle-aged men and 2% of middle-aged women in Finland. It is feared that the incidence of the illness will continue to rise with the increasing obesity of the population. A typical patient with sleep apnoea is a man over 35 years of age or a postmenopausal woman. At least 0.3% of all adult men below retirement age su¡er from moderate-to-severe sleep apnoea. The illness also occurs in women. The incidence of sleep apnoea peaks among men aged 50^59 years (Appendix 3).
Respiratory disruptions during sleep are common in the elderly even though they do not snore as often as the middle aged. Of people aged over 65 years, one in four has an apnoea index of more than 10. However, the number of those with symptomatic sleep apnoea is lower among the elderly than among middle-aged men, estimated at 0.5^1%.
In the extensive Health 2000 survey, carried out on 10 000 subjects aged over18 years by the National Public Health Institute, approx. 7% of the Finns (approx.13% of men and approx. 3% of women) reported having experienced weekly sleep disruptions, and approx.1% (approx. 2% of men and under 0.5% of women) reported having been diagnosed with sleep apnoea.
The incidence of sleep apnoea in 5-year-old children in Finland is estimated to be approx. 2%. The evaluation of the incidence of sleep apnoea in children is complicated by the fact that, in children, the illness is partly related to the amount of adenoid tissue in the throat, and the incidence of the illness may £uctuate at di¡erent ages. Studies conducted outside Finland indicate that, among children aged 4^6 years, 7^10% snore, and among children aged 0.5^6 years, 2^3% su¡er from sleep apnoea.
No di¡erence in the incidence of sleep apnoea with regard to sex has been found among children, even though boys snore slightly more than girls. Figure 2 shows an estimate of the sleep apnoea status in Finland. According to the HILMO register of Stakes, 6645 patients were diagnosed with sleep apnoea; the number of treatment periods was 8993; and the number of hospital days was 12 803 in 2000. Treatment duration averaged 1.4 days. In 2000, 2908 patients were hospitalised for snoring, and the number of treatment days was 3582 ( Figure 3 ). The halt in the rise in patient numbers and treatment days was not caused by a reduction in the incidence or alleviation of the illness, but rather by the fact that sleep registration follow-ups requiring many hospital days have been reduced by increasing outpatient activity.
The number of continuous positive airway pressure (CPAP) devices used for the treatment of sleep apnoea has been rising steadily in the 1990s. The number continues to rise. In 2000, there were approx. 150 users of CPAP devices per 100 000 inhabitants in Finland. These ¢gures re£ect the number of diagnosed cases of moderate-to-severe sleep apnoea. Figure 4 shows the regional di¡erences in 2000 for the hospital districts (68^598/ 100 000).
Apart from sleep apnoea, partial upper airways obstruction also involving increased respiratory resistance but no clear respiratory interruptions should be considered. Its precise incidence is still not known.
CAUSES AND RISK FACTORS
The development of upper airways obstruction causing sleep apnoea is in£uenced by the physiology of sleep (Appendix1), and factors relating to anatomy and physiology (Tables 5 and 6 ).
CONSEQUENT EFFECTS
The quality of life, the alertness, and the functional ability of a patient su¡ering from sleep apnoea are impaired by fatigue, concentration di⁄culties, mood changes and impaired libido. Cardiovascular symptoms in sleep apnoea patients relate to hypoxia and increased blood CO 2 levels during sleep, an increase in nocturnal respiratory e¡ort, and an increase in sympathetic nervous activity (Table 7) . Sleep apnoea causes vasoconstriction and elevates both systemic and pulmonary blood pressure.
SPECIAL FEATURES OF SLEEP APNOEA IN CHILDREN
The most important risk factors of sleep apnoea in children are enlarged adenoids and tonsils. Moreover, sleep apnoea is more common in children su¡ering from various syndromes or mental retardation than in children in general. However, sleep apnoea is rare during infancy, except in children with an apparent life-threatening event (ALTE), up to 50% of whom su¡er from sleep apnoea. Mental retardation and the various syndromes in children are associated with an increased disposition to sleep apnoea. Removal of hyperplastic adenoid mass may cure sleep apnoea in a child. If surgical interventions are unsuccessful, CPAP treatment is an option to be considered. Obesity and thickness of neck in a child increase the occurrence of sleep apnoea.
Sleep apnoea in children may also result from mandibular deviation and malocclusion in childhood. About 202 5% of children and adolescents have malocclusions where the anterior growth of the mandible is not parallel with the growth of the other facial parts. Nasal congestion, large adenoid tissue mass and oral breathing have an unfavourable e¡ect on facial bone growth. Children su¡ering from these problems develop a facial structure where the growth of the mandible is directed down rather than frontally. The face does not grow in depth, and the airways do not gain enough space. Adenoid tissue surgery and orthodontics are used to guide maxillomandibular growth and occlusion development to the right direction.
Daytime fatigue or obesity are not typical symptoms in paediatric sleep apnoea, except in a very severe condition. In children, sleep apnoea causes restless sleep, snoring, sweating, recurrent upper respiratory tract infections, hyperactivity, impaired concentration, learning di⁄culties, and oral breathing. In severe sleep apnoea, serious cardiovascular complications, for example, have been reported.
GOALS AND MEANS OF THE PROGRAMME
The goals for the prevention, treatment and rehabilitation of sleep apnoea for 2002^2012 are presented in Table   600 8 and discussed in more detail later. Table 9 shows the means of achieving these goals.
PREVENTIONOF SLEEP APNOEA AND ITS CONSEQUENCES

Possibilities of prevention
The risk of developing sleep apnoea may be reduced by in£uencing the behaviour of the individual concerned, by facilitating good treatment of the predisposing illnesses (primary prevention) and also by improving the early detection of sleep apnoea and the motivation of the patient with regard to his own treatment (secondary prevention).Good treatment of sleep apnoea, rehabilitation and therapy of concomitant illnesses may help reduce the individual handicap caused by the illness (tertiary prevention). The basis for the prevention comprises both individual (risk groups) and national interventions (Tables10^12).
The improvements in the standard of living have resulted in changes in the society and in lifestyles that predispose to obesity. Nationwide prevention of obesity requires interventions at di¡erent levels of society to further reduce the dietary intake of fat and to increase the physical activity of the population.
This means limiting the energy content of food, development of school and workplace canteen food, nutrition and exercise guidance, development of light tra⁄c, extensive education and cooperation as well as research.
Persistent upper respiratory tract infections and other factors complicating nasal breathing, such as large adenoids and tonsils, allergy or irritation due to poor ambient air, predispose to the development of sleep apnoea as early as in childhood. In£uenza, haemophilus and pneumococcal vaccines are used to counteract infections. At national level, reminding people about the importance of hand washing can reduce the contagiousness of respiratory infections. Good hygiene in daycare centres has also been found to reduce infections in children. Oral breathing guides maxillomandibular growth and occlusion development in an unfavourable direction. As a result, the anatomy of the upper respiratory tract develops to increase the risk of sleep apnoea. Rheumatoid arthritis, particularly juvenile RA or other rare illnesses such as acromegaly and hypothyroidism in£uence the development of jaw size and position. Early detection and treatment of these illnesses is a part of the prevention of sleep apnoea.
Smokers have been found to have more respiratory interruptions than non-smokers. The di¡erence is eliminated with the cessation of smoking. Giving up smoking reduces the tendency to snore as the incidence of respiratory tract infections and mucosal membrane oedema of the airways decreases. The elimination of carbon monoxide from the blood results in more e¡ective nocturnal oxygenation. The cessation of smoking often results in weight gain and, therefore, concomitant support with weight control is needed. The consensus treatment recommendation on abstinence from smoking to be issued by the Finnish Medical Society Duodecim in 2002 will provide tools for guidance and treatment.
Alcohol decreases muscle tone in the nasopharynx and impairs the function of the CNS regulatory mechanisms. Excessive use of alcohol and heavy drinking are the commonest promoters of the risk factors of sleep apnoea. Alcohol also causes weight gain, increases central obesity and visceral fat. A person with risk factors of sleep apnoea should be instructed to avoid excessive use of alcohol.
CNS depressants impair sleep apnoea. Decreased use of these agents would reduce the risk of sleep apnoea in the population. Misuse of CNS depressants should be tackled. The history of snoring should be recorded and risk patients considered when prescribing the medication.
Prevention of sequelae
Once sleep apnoea has been diagnosed, the treatment should be directed at the factors causing sleep apnoea in each individual case. Successful treatment of sleep apnoea removes daytime fatigue and improves the quality of life.
Eighteen per cent of the fatal road tra⁄c accidents examined by the road tra⁄c investigation teams are caused by fatigue or falling asleep at the wheel. It is estimated that people with untreated sleep apnoea are at a 6^7-fold risk of having an accident compared to the rest of the population. Controlled asymptomatic sleep apnoea does not a¡ect driving. The risk in tra⁄c caused by se- vere sleep apnoea is considered so high that, in cases when the treatment is not e¡ective or the patient is reluctant to undergo treatment, the driving licence authorities should be noti¢ed. According to current Finnish legislation, a written consent from the patient is always needed for this. When issuing medical certi¢cates for driving licences, doctors should be able to refer all patients with symptoms or anatomy suggestive of sleep apnoea to further evaluations. The application of the sleepiness questionnaire in Appendix 2 could be a practical tool. If the patient's score is11or higher, specialist consultation should be considered. The questionnaire can also be applied to age group check-ups in occupational health care.
A professional driver with untreated sleep apnoea should be urgently referred to the initiation of the treatment and, if necessary, sick leave should be considered until the treatment can be initiated.
The treatment of sleep apnoea reduces elevated blood pressure. If a patient with sleep apnoea su¡ers from hypertension and the illness is not properly treated, treatment should be organised. On the other hand, when refractory hypertension is detected, the potential role of sleep apnoea should be considered.
Out of sleep apnoea, asthma and COPD, one is not the cause of the other. However, these illnesses are so common that there are patients with concomitant sleep apnoea and asthma, or sleep apnoea and COPD, or all three. Untreated asthma or COPD further impair the oxygen uptake in a patient with sleep apnoea. Allergic symptoms often related to asthma hamper nasal breathing. Proper treatment of asthma, allergies and COPD alleviates the severity of sleep apnoea.
DIAGNOSIS OF SLEEP APNOEA Diagnosis of sleep apnoea
When sleep apnoea is suspected, the ¢rst thing to do is to establish whether the patient's symptoms indicate sleep apnoea and whether further evaluation of this diagnosis is of primary importance. The patient may su¡er from another illness causing fatigue or health hazards, the further evaluations of which should be initiated prior to or simultaneously with the evaluation for sleep apnoea. At the second phase, the objective is to con¢rm or exclude sleep apnoea and evaluate the severity of the diagnosed illness. The phases of sleep apnoea diagnosis are shown in Fig. 5 , with more details inTable 13 and Appendixes 2, 4^8.
Basic evaluations: establishing sleep apnoea suspicion and the risk of sleep apnoea
The most important tool in the evaluation is the recording of patient history using a questionnaire on symptoms.
The illness develops slowly, and the patient may consider the symptoms to be part of his personality without identifying them. A sleepiness questionnaire is used to collect information on the severity of the symptoms (e.g. ESS=Epworth Sleepiness Scale, Appendix 2).Central symptoms, risks and concomitant illnesses are established when recording the history and, in connection with a physical examination, attention is paid to the general appearance, body mass index (BMI) (Appendix 4) and the blood pressure of the patient, as well as nasal, pharyngeal and facial structure (Table 13) .
If the symptoms, ¢ndings and risk factors primarily suggest (1) health problems other than sleep apnoea (depression, hypothyroidism, diabetes) or (2) risk factors of sleep apnoea or, at most, mild sleep apnoea, further evaluations, symptoms follow-up, health education and patient guidance in accordance with the problem will be implemented within primary health care. Should the ¢ndings suggest moderate or severe sleep apnoea, further evaluations will be performed in specialist care. Appendix 5 shows a checklist for a GP/occupational health physician for referrals to sleep apnoea evaluations. The referral will be directed in accordance with the allocated duties to an outpatient unit specialising in sleep evaluation, most often an outpatient department of pulmonary diseases at present.
Specialist evaluations and diagnostic methods
If an obese patient has typical indications of sleep apnoea, the diagnosis is primarily made on the basis of sleep registration. The need for other examinations is de¢ned individually. As a general rule, sleep apnoea evaluations are complemented by an ENT specialist consultation. This is necessary in order to ¢nd the patients who would bene¢t from surgical treatment.The purpose of the consultation is also to assure nasal breathing with regard to potential CPAP treatment. If the structural deviations of the face are distinct, evaluations by a maxillofacial surgeon and a specialist in orthodontics on the deviations are included. Appendix 6 lists examples of situations when consultation with a specialist from outside the specialty concerned should be considered. Diagnostic evaluations of patients under 15 years of age are arranged by paediatric units. For patients under 2 years of age, extensive sleep registration is always recommended. Table  14 shows the specialist tools for the evaluation of sleep apnoea.
Limited sleep registration monitors airways patency, respiratory resistance, movements of the chest and legs and changes in oxygen saturation measured by pulse oxymeter expressed as ODI (¢gure describing falls in oxygen saturation during sleep). Extensive sleep registration is the most expensive form of sleep registration. Apart from other changes during sleep, it is used to monitor the di¡erent phases of sleep with the help of electroencephalography (EEG) (Appendix 7). Extensive evaluation is necessary in special cases even though the diagnosis can normally be con¢rmed by limited sleep registration (Table 15 ). The unit performing the evaluation gives a clear report on the results, including information about the diagnostic methods as well as the quantitative results. Being able to relate the results from the registration to the symptoms of the patient is necessary.
Di¡erential diagnostics
Daytime fatigue also has causes other than sleep apnoea. With regard to di¡erential diagnosis, the most common causes of daytime fatigue are listed inTable 16.
Alternatives for the di¡erential diagnosis of sleep apnoea in children are shown inTable 17.
CHAINOF TREATMENT
Patients with sleep apnoea are encountered at all levels of the health-care chain both in primary and occupational health care and in specialist health care (Table 18 ). The prevention, treatment and rehabilitation of sleep apnoea include many tasks that are implemented outside the health centre and hospital system. Patient organisations have a central role, but the municipal social services and exercise departments as well as the private sector participate in o¡ering services suitable for patients with sleep apnoea. The prevention, treatment and follow-up of sleep apnoea are a joint e¡ort of all these sectors.
The tasks of primary health care are the prevention of sleep apnoea, the treatment of patients with mild-tomoderate sleep apnoea as agreed in cooperation with specialist health care, and the treatment of concomitant illnesses. The tasks of specialist health care are con¢rm-ing the sleep apnoea diagnosis, drafting a plan for the treatment and rehabilitation of the illness, initiating CPAP treatment, implementing other specialist healthcare measures and supporting primary health care in implementing further treatment and follow-up as agreed.
The instruments designed for the diagnosis and treatment of sleep apnoea have become simpler. With support from specialist health care, it is possible to screen the patients with sleep apnoea primarily within primary health care. Problematic cases should be referred to specialist treatment. A self-regulating CPAP device adjusts the pressure level automatically to comply with the patient's needs, rendering admissions to hospital for pressure titrations redundant. The device records deviating respiratory events and the actual duration of use.
As the number of sleep apnoea patients receiving treatment increases, the task of monitoring sleep apnoea will be increasingly directed to primary health care with specialist consultations in problematic cases when necessary. Active treatment chains require (1) agreement between the di¡erent levels of health care, (2) education of primary health care and (3) research.
The treatment chain and the treatment lines should be adjusted regionally due to varying patient numbers, arrangements for cooperation and treatment opportunities. Appendix 9 shows an example of the treatment lines within primary health care.
TREATMENT Goals and methods
The aim of the treatment of sleep apnoea is to eliminate the respiratory interruptions. If this succeeds, the treatment is curative. Even if the respiratory interruptions are not entirely eliminated, they can be controlled by various treatment methods so that the patient feels cured. It can also be presumed that the risks deriving from an untreated illness are avoided. Table 19 shows the goals of the treatment of sleep apnoea. A summary of the di¡erent treatment methods is presented in Table  20 . Central factors in choosing the mode of treatment are the cause of the respiratory obstruction and the severity of the disease.
Conservative treatment
Weight reduction and weight control
Weight reduction as a treatment of sleep apnoea is of primary importance for all obese patients with sleep apnoea. A treatment programme for obesity is initiated if the patient is at least signi¢cantly overweight (BMI Z30 kg/m 2 ). In the range of slight overweight (BMI 252 9.9 kg/m 2 ), weight reduction is necessary if the patient su¡ers from central obesity (waist circumference 490 cm in women and 4100 cm in men).
The objective of the treatment in adults is permanent weight loss of 5^10%.The target weight does not need to be the normal weight, which is usually an unrealistic objective for severely obese patients.Obese people tend to continue gaining weight and, particularly in cases of slight overweight, arresting the accumulation of weight is already a signi¢cant initial result. The treatment of obesity is mainly implemented within primary health care. Severe, pathological obesity that is associated with sleep apnoea and requires weight reduction can be treated within specialist care.
Weight control after weight reduction requires permanently lowered energy intake and/or greater energy consumption than prior to the weight reduction. The treatment of obesity includes expert guidance in permanent life-style changes. The Medical Society Duodecim has published a consensus treatment recommendation 
Position therapy
Most patients snore less when they lie on their side. Attaching a tennis ball to the back of the nightgown may prevent supine sleeping, or various cushions or supports can be placed under the back. Position treatment can help patients with mild sleep apnoea but motivating patients to adopt this mode of treatment is problematic.
The long-term bene¢ts of this treatment have not been established.
Medicines
Several di¡erent medicines have been used in the treatment of sleep apnoea but, in repeated controlled studies, none of them has proved more e⁄cient than placebo. Progesterone derivatives have yielded the best results. New medicines are being developed, but their introduction to the market may take years. Sleep apnoea may be associated with depression, which must be treated appropriately using modern antidepressants. If sleep apnoea is associated with severe obesity, pharmacotherapy may be considered. There are two medicines, orlistate and sibutramide, for this. If the patient su¡ers from moderate-to-severe sleep apnoea, his BMI is 432 kg/m 2 and a loss of weight of at least 4 kg has been reached prior to the initiation of pharmacotherapy in an 8 -week dieting programme, the Social Insurance Institution can grant basic reimbursability for an anorexigenic medicine on the basis of Medical Statement B.
Devices in£uencing the position ofthe mandible and the tongue, and orthodontic treatment
There are various devices in£uencing the position of the tongue and the mandible. Devices preventing the retraction of the tongue or devices that protrude the mandible can be placed in the mouth. These devices help prevent snoring in particular. The device may present a solution for patients with problematic snoring without elevated apnoea indices, and for patients with mild sleep apnoea. The bene¢ts of the device are evaluated by sleep registration. Orthodontic treatment plays a role in the prevention of sleep apnoea in children. In adults, orthodontic treatment is an essential part of the surgical treatment of the mandible.
Continuous positive airway pressure treatment
The principle of CPAP treatment is to create positive airway pressure, an ''air splint'', using a nasal mask and an air-blowing device, thereby counteracting the collapse of the airways. It in£uences the widening of the upper respiratory tract also indirectly by increasing the residual volume of the lungs.
CPAP treatment can be o¡ered to patients with diagnosed sleep apnoea. CPAP treatment has been found to correct respiratory disturbances during sleep. It is the primary mode of treatment in severe sleep apnoea and in some cases of moderate sleep apnoea, keeping the importance of weight control in mind. The indications of CPAP treatment are shown inTable 22. There are no actual contraindications to CPAP treatment, but not all patients adapt to the treatment. Some conditions cause more problems than usual in connection with CPAP treatment and can be considered relative contraindications (Table 23 ).
In order for CPAP treatment to be e¡ective, it should be used at least ¢ve nights a week, 3^4 h/night. The treatment does not cure the illness. CPAP treatment is initiated at a health-care unit with su⁄cient facilities. Once the correct pressure level (usually 5^15 cmH 2 O) has been attained, sleep is usually normal and there should no longer be any abnormal arousals. After the initiation, the patient takes the device home for a trial of a few weeks, after which the treatment success is evaluated. Once the CPAP treatment has been successfully initiated and the patient has been instructed in the use of the device, the treatment can be monitored on an annual basis. Follow-up visits may be arranged as appointments with a nurse or a rehabilitation instructor trained for the follow-up. The treatment device will be inspected and serviced at the follow-up visits. Should it be found during the follow-up visit that the overall situation of the patient has changed or the patient has other health problems, he will be referred to a doctor. The aim is to arrange the follow-up preferably within primary health care.
Over 90% of the sleep apnoea patients using the CPAP device feel that they have obtained bene¢t from the treatment. Most adverse e¡ects of CPAP treatment are minor. Problems arise in 30^50% of the patients, but they do not usually result in the discontinuation of the treatment if the patient feels that the symptoms have Poor treatment compliance is predicted by previous corrective surgery of the pharynx and a mild illness with few symptoms. If the patient does not adapt to CPAP treatment, it is important to make sure that other forms of treatment and follow-up will continue.
Surgical modes of treatment
The objective of surgical treatment of sleep apnoea is to widen the airways by surgery. The surgery can be directed to soft tissue or to bony structures.The airways are widened by the removal of an isolated obstructive factor, such as large tonsils or nasal polyps. The pharynx can be widened by the removal of the surrounding tissues, which is a secondary method with regard to CPAP treatment, or by changing the relative locations of the tissues by maxillomandibular osteotomies. Since scienti¢c evidence on the usefulness of the surgical treatments is still partly contradictory, more studies are needed. Surgical treatment methods and their e¡ects are shown inTable 26.
REHABILITATION AND DEVICES Rehabilitation
In the rehabilitation of a patient with sleep apnoea, the primary focus must be on directing the patient toward self-care and encouraging him to adopt it. Exercise, weight loss, weight control, abstinence from smoking, and prevention of the overuse of alcohol are essential features of self-rehabilitation. As a general rule, rehabilitation should be organised as outpatient rehabilitation in connection with primary health care. Medical rehabilitation includes o¡ering advice about rehabilitation and available rehabilitation services, evaluating the patient's need for rehabilitation and the di¡er-ent rehabilitation options on the basis of the patient's working and functioning capacity, occupational rehabilitation, physiotherapy and other similar therapies, adaptation therapy, device services, and rehabilitation guidance. These methods can be used either in outpatient care or during institutional rehabilitation periods. Adaptation therapy involves guiding the patient and his family in postdiagnostic life management. Adaptation therapy is usually group therapy. In most cases, specialised health-care units responsible for the treatment of sleep apnoea organise survival course-like adaptation therapy, for which they select the patients. The healthcare units plan and organise the courses either by themselves or in collaboration with other organisations. Having the patient's family attend the courses is considered essential as regards the successful rehabilitation of the patient. Rehabilitation institutes o¡er adaptation therapy courses as well. Patients with a payment agreement from specialised or primary health care can be accepted, but patients usually apply for the courses through the Social Insurance Institution on the basis of the treating physician's statement.
The main task of the Social Insurance Institution is to organise the rehabilitation of severely handicapped patients. SII also organises other forms of individual rehabilitation and courses, for which patients are selected on the basis of the treating physician's medical statement B within annual resource limits. In 2000, SII funded the rehabilitation of 219 patients with sleep apnoea. Of these, 123 were in working life and received a rehabilitation allowance from the Social Insurance Institution.
If a patient with sleep apnoea works in tra⁄c or in another profession requiring exceptional alertness and precision, and if the treatment is not successful in eliminating all his symptoms, means of occupational rehabilitation can be considered. The objective is to ¢nd a suitable job for the patient, thus allowing him to participate fully in working life.The services of occupational rehabilitation are vocational guidance, rehabilitation research, experiments with work and training, prework training, on-the-job training, ¢nancial support, devices, and renovations to the workplace. Occupational rehabilitation also includes training subsidy.The Social Insurance Institution is under an obligation to organise occupational rehabilitation unless it is arranged through employment pension legislation or employment initiatives.
Device services
The positive airway pressure device (CPAP device) used in the treatment of sleep apnoea is a medical device which falls under the Act and the Decree on Medical Rehabilitation, and the sections on devices in the Act on Public Health and the Act on Specialised Health Care. Device services include evaluating the patient's need for devices, adapting the device for the individual patient and delivering it for either temporary or permanent use, teaching the patient to use it, monitoring its use, and maintaining it in working order.
The unit delivering the device is responsible for providing the patient with su⁄cient instructions on its use.The unit is also responsible for keeping it functional and safe. In practice, the unit either arranges regular maintenance of the device, or purchases the service elsewhere. This is possible only when the device register is functional. The Finnish Lung Health Association has collaborated with two hospital districts over the design of a respiratory device register, which could be developed into a functional system for wider use. According to existing legislation, a health care unit cannot leave responsibility for device maintenance to the patient alone.
Apart from the actual device, the CPAP treatment package includes a mask, headgear, and tubes. Supplies for the use of patients with sleep apnoea are distributed only by specialised health care, since selecting the supplies, training the patients, and monitoring the use of the device demand specialised expertise.
In the near future, primary health care may be assigned greater responsibility for providing device services according to a local agreement.The importance of other organisations in providing device services may also increase in the future.
SOCIAL SECURITY
The social security of patients with sleep apnoea is based on the basic Finnish social security system. Devices for the treatment of sleep apnoea are lent to the patient (see paragraph ''Medicines''). The patient can apply to the Social Insurance Institution, for example, for reimbursement of treatment and medical costs, disability allowance, and care allowance. If the patient is unable to work, he can apply to the Social Insurance Institution for sickness allowance, and either to the Social Insurance Institution or to the patient's employment pension institution for disability pension.The patient can apply to the municipal social sector for services de¢ned in the Act on Services for Disabled Persons.There are no speci¢c decrees concerning this patient group, with the exception of the reimbursability of anorexigenic medicines on certain conditions (see paragraph ''Device Services'').
COSTS
American studies have indicated that untreated sleep apnoea nearly doubled the use of health services compared to the control population. On the other hand, successful and motivating treatment of sleep apnoea signi¢cantly decreased the use of health services compared to the situation prior to treatment.Comparable studies have not been conducted in Finland.
There are no exact calculations of the costs of treatment for sleep apnoea. The costs can be estimated by proportioning the number of patients to the known average prices of the services. The price of an individual patient's treatment can be estimated on the basis of the prices of di¡erent procedures and treatments suitable for most patients (Appendix11). Realistic treatment costs are represented by the calculations made in the Varsinais^Suomi hospital district, which indicate that the direct annual costs of the diagnosis and the treatment of sleep apnoea amount to more than 1.68 million euros in this hospital district alone.
The treatment costs of patients with mild sleep apnoea can consist of, for example, doctor's fees and laboratory tests in primary health care, and participation in weight loss groups and exercise groups.The treatment of such patients amounts to approx. 151A in the initial phase, and further expenses are approx. 101A per annum. Patients in the specialised health-care sector are usually patients on CPAP treatment. The CPAP treatment of each new sleep apnoea patient costs approx. 1682h in the ¢rst year, after which the annual costs of successful treatment amount to approx. 252h. In practice, 5 years of CPAP treatment cost approx. 2691h. After the 5-year period, the costs include not only annual monitoring but also the replacement of the device. Recent trends suggest that if 1000 new patients require treatment every year, and if 4000 previously treated patients are monitored at the same time, as indicated by the statistics from 1998, 2.7 million euros are spent on CPAP treatment per annum, not counting the costs of device replacement. In1998,1000 CPAP devices passed their recommended usage age of 5 years, which added 0.5 million euros to the expenses. The calculations do not account for the treatment of problematic patients requiring special examinations that also add to the expenses.
Half of the sleep apnoea patients under 65 years of age on CPAP treatment are in working life. If the patient does not su¡er from other illnesses, sleep apnoea alone is not a common cause of incapacity for work. No statistics are available for sick leaves or pensions accorded on the basis of diagnosed sleep apnoea.
IMPLEMENTATIONOF THE PROGRAMME Information, training and guidance
The implementation of the sleep apnoea programme calls for the distribution of information, education of key groups, and continuous guidance. Key groups include people who are at a high risk of developing sleep apnoea, those with sleep apnoea, and those directly involved in the treatment of sleep apnoea. Key groups also include people who can actively help prevent sleep apnoea in their work (planners, product designers), people who inform others of issues concerning health and illness (reporters, representatives of organisations, and manu-facturers of devices), and people who are in a position to decide how public resources are used.
The responsibility for distributing information and educating key groups can be shared so that organisations such as the Finnish Lung Health Association, the Pulmonary Association HELI and the Finnish Sleep Apnoea Association are responsible for informing their own members and, in part, the general public. Together with experts, the organisations produce material needed in patient education. To this end, organisations can receive funding from the Finnish Slot Machine Association, for example. The Social Insurance Institution distributes information on social security and the ways in which the SII supports the patient's capacity for work.The authorities are responsible for informing experts and training them in collaboration with di¡erent associations and societies.These include the Municipal Doctors Association, the Orthodontic section of the Finnish Dental Society Apollonia, the Finnish Dental Association, the Association of Finnish Pulmonary Physicians, the Finnish Society of Clinical Physiology, the Finnish Society of Clinical Neurology, the Association of Finnish Otolaryngologists, the Finnish Paediatric Association, the Finnish Neurological Society, the Finnish Federation of Nurses, the Finnish Internal Medicine Association, the Finnish Sleep Research Society, the Finnish Association for General Practice, the Association of Oral and Maxillofacial Surgery, the Union of Health and Social Care Professionals, the Association of Health Centre Dentists and the Finnish Sleep Federation. Provincial guidance and education will be the joint responsibility of hospital districts and provincial governments, whereas health centres will be responsible for local guidance and education.The media have an important opportunity to initiate debate on the programme and to support its goals and principles (Table 27) .
Special attention must be paid to the training of new health-care professionals. The fundamental principles of the sleep apnoea programme should be included in the curriculum of health-care institutes, medical faculties, and specialist training programmes. The possible need to train experts in sleep apnoea, such as respiratory nurses, sleep technicians and weight loss programme leaders, for practical work should be considered in the implementation of the programme. Hospital districts should prepare collaborative programmes for the prevention and treatment of sleep apnoea to be applied locally. Hospitals have reported positive experiences of regular meetings of working groups on sleep attended by representatives of the appropriate specialised branches. The revision of the treatment recommendations can be accomplished by preparing a Duodecim consensus treatment recommendation after the programme has been launched.
Research and monitoring
Universities, health-care institutes, health-care associations and individual researchers have conducted research into sleep apnoea in Finland. In Health 2000 survey, a comprehensive study by the National Public Health Institute, the sleep of the population was one of the subjects studied. In future, the study can be used in the monitoring of the programme. However, more population studies on the prevalence and signi¢cance of the illness are needed. Studies on the mechanism of sleep apnoea, the risk factors, the methods of treatment and their cost-effectiveness are also needed. Table 28 lists the development needs for the research and monitoring of the sleep apnoea programme. Joint meetings/seminars of sleep apnoea researchers should be arranged annually.
Creating a well-designed, functional and continuous system of quality control and direction is necessary for the implementation of the programme. Special attention must be paid to the monitoring of the success of sleep apnoea prevention and treatment. Existing registers of respiratory devices and material withdrawn from use should be developed for use in the monitoring of treatment success and patient £ow.The system of monitoring overweight people at a high risk of developing sleep apnoea should be developed so that the treatment of the illness can be initiated early on. The provincial applications of the sleep apnoea programme should include mechanisms for monitoring the implementation of the provincial programmes. The Finnish Lung Health Association appoints a monitoring group to support and evaluate the implementation of the sleep apnoea programme. A more comprehensive follow-up report and evaluation will be made once the ¢rst-half of the programme has been completed.
Costs of the programme
The costs of the programme for the prevention and treatment of sleep apnoea mainly consist of communications, training and programmes for quality control and direction. These are not additional expenses, but expenses relating to the normal functions and development of health-care units and associations. The communications, training, production of material and development of strategic forms of operation relating to the launch of the programme should receive ¢nancial support from health-care development funds (e.g. from the Finnish Slot Machine Association). The additional expenses of the launch of the programme (training, communications, guidance, monitoring) amount to under one million euros in 2002^2006.
If the programme is implemented and the quality of the prevention and treatment of sleep apnoea is improved, sleep apnoea can be treated with the best possible cost-e¡ect ratio. If the programme is not implemented, the costs caused by sleep apnoea, which has proved to be a national health problem in Finland, will increase signi¢cantly. 
SUMMARY
